Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Reliv' International (RELV) Competitors

Reliv' International logo

RELV vs. IBIO, AEON, NRBO, OBSV, CPHI, GRAY, ATXI, ORGS, CANF, and ADXS

Should you be buying Reliv' International stock or one of its competitors? The main competitors of Reliv' International include iBio (IBIO), AEON Biopharma (AEON), NeuroBo Pharmaceuticals (NRBO), ObsEva (OBSV), China Pharma (CPHI), Graybug Vision (GRAY), Avenue Therapeutics (ATXI), Orgenesis (ORGS), Can-Fite BioPharma (CANF), and Ayala Pharmaceuticals (ADXS).

Reliv' International vs. Its Competitors

Reliv' International (NASDAQ:RELV) and iBio (NYSE:IBIO) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Reliv' International has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Reliv' International has higher revenue and earnings than iBio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reliv' International$35.06M0.13-$440KN/AN/A
iBio$400K45.22-$24.91M-$1.74-0.51

8.0% of Reliv' International shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 31.2% of Reliv' International shares are held by insiders. Comparatively, 2.8% of iBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, iBio had 4 more articles in the media than Reliv' International. MarketBeat recorded 4 mentions for iBio and 0 mentions for Reliv' International. Reliv' International's average media sentiment score of 0.00 equaled iBio'saverage media sentiment score.

Company Overall Sentiment
Reliv' International Neutral
iBio Neutral

iBio has a net margin of 0.00% compared to Reliv' International's net margin of -0.61%. Reliv' International's return on equity of -1.89% beat iBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Reliv' International-0.61% -1.89% -1.31%
iBio N/A -73.15%-45.51%

iBio has a consensus target price of $3.50, suggesting a potential upside of 291.94%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Reliv' International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reliv' International
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
iBio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

iBio beats Reliv' International on 8 of the 14 factors compared between the two stocks.

Get Reliv' International News Delivered to You Automatically

Sign up to receive the latest news and ratings for RELV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RELV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RELV vs. The Competition

MetricReliv' InternationalPharmaceutical Preparations IndustryStaples SectorNASDAQ Exchange
Market Cap$4.40M$1.05B$16.10B$10.68B
Dividend YieldN/A4.84%3.21%4.83%
P/E Ratio-22.911.3117.6927.38
Price / Sales0.1329.7047.60132.78
Price / Cash44.5317.6314.6930.35
Price / Book0.408.037.226.68
Net Income-$440K-$7.47M$678.09M$276.27M

Reliv' International Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RELV
Reliv' International
N/A$2.52
flat
N/AN/A$4.40M$35.06M-22.9191
IBIO
iBio
2.1183 of 5 stars
$0.87
-0.3%
$5.00
+477.2%
-70.4%$17.03M$400K-0.50100Analyst Forecast
Gap Up
AEON
AEON Biopharma
0.5678 of 5 stars
$0.92
-1.6%
N/A-98.6%$10.71MN/A5.115Gap Up
NRBO
NeuroBo Pharmaceuticals
N/A$1.06
-1.9%
N/A-67.9%$9.13MN/A0.0010High Trading Volume
OBSV
ObsEva
N/AN/AN/AN/A$7.94MN/A0.0050
CPHI
China Pharma
0.1641 of 5 stars
$1.98
+0.8%
N/A-92.7%$6.44M$4.40M0.00250Short Interest ↑
Gap Down
GRAY
Graybug Vision
N/A$3.25
+1.6%
N/A-21.3%$5.11MN/A-1.8827High Trading Volume
ATXI
Avenue Therapeutics
1.9749 of 5 stars
$0.75
flat
N/A-65.4%$2.38MN/A0.044
ORGS
Orgenesis
1.5033 of 5 stars
$0.47
+326.9%
N/A-92.9%$2.26M$662K0.00150Gap Up
CANF
Can-Fite BioPharma
2.376 of 5 stars
$0.59
-1.8%
$14.50
+2,353.1%
-82.5%$2.09M$560K-0.338Short Interest ↑
ADXS
Ayala Pharmaceuticals
N/A$0.03
-66.6%
N/A+23.3%$1.42M$3.24M0.0020Gap Down

Related Companies and Tools


This page (NASDAQ:RELV) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners